Spontaneous adverse drug reaction reports on patients with cirrhosis: analysis of the nature, quantity and quality of the reports by Weersink, R.A. (R. A.) et al.
LETTER TO THE EDITOR
Spontaneous adverse drug reaction reports on patients
with cirrhosis: analysis of the nature, quantity
and quality of the reports
R. A. Weersink1,2 & K. Taxis1 & E. P. van Puijenbroek1,3 & S. D. Borgsteede2,4
Received: 11 June 2019 /Accepted: 7 February 2020
# Springer-Verlag GmbH Germany, part of Springer Nature 2020
Patients with cirrhosis have a high risk of adverse drug
reactions (ADRs), in part due to alterations in drug phar-
macokinetics [1, 2]. Less is known about pharmacody-
namic alterations that could occur because of the patho-
physiology of cirrhosis. For example, up to 50% of pa-
tients with cirrhosis and ascites that use ibuprofen suffer
from renal impairment because ibuprofen potentiates the
renal vasoconstriction occurring in cirrhosis [3]. Data on
pharmacokinetic changes are obtained during pre-
marketing studies. These are usually single-dose studies,
with few participants. Patients with severe cirrhosis are
frequently not included [2]. Hence, potential drug safety
issues in patients with cirrhosis are often revealed in the
post-marketing setting. To obtain more information on
ADRs in these patients, we rely on information from clin-
ical practice. One of the tools to do so is spontaneous
reports, provided that the quality of clinical documenta-
tion is sufficient. Spontaneous reports have been studied
in other populations in which pharmacokinetic and phar-
macodynamic alterations could occur (e.g. infants [4], el-
derly [5]), yet no study focused on patients with cirrhosis.
Therefore, in this study, we aim to determine the number
of spontaneous ADR reports on patients with cirrhosis
and the quality of documentation. Furthermore, we
analysed the nature of the ADR reports.
We extracted all reports submitted between January 1990
and July 2018 to the Netherlands Pharmacovigilance Center
Lareb mentioning “cirrhosis” in the medical history, clinical
information or narrative. We excluded duplicate reports, re-
ports with cirrhosis as ADR and reports with an uncertain
diagnosis of cirrhosis. The diagnosis was considered uncertain
if the report mentioned “possible cirrhosis” or if a liver trans-
plantation was described with no details on disease recur-
rence. Moreover, the report was excluded if it mentioned “pri-
mary biliary cirrhosis”, since a large part of these patients does
not have cirrhosis yet [6]. The content of the included reports
was quantitatively described. The suspected drugs were com-
pared with prescribing recommendations for cirrhosis [7] to
assess if any drugs with additional ADR risks were involved.
In total, 50 reports were retrieved from the Lareb database.
Twelve were excluded because they were duplicates (n = 2),
reported about cirrhosis as ADR (n = 2) or reported about
patients with an uncertain diagnosis (n = 8). Table 1 shows
some characteristics of the 38 included reports. The severity
of cirrhosis was described in 12 reports (32%) and 7 (19%)
used a validated severity classification (i.e. Child-Pugh
classification).
A total of 58 suspected ADRs were reported and most
frequent were as follows: thrombocytopenia, a rash and
seizures (all reported thrice). The reports included 43
suspected drugs with pegylated interferon-alpha-2a as
most commonly involved (n = 3). Of these suspected
drugs, four were known to have additional risks in cirrho-
sis (i.e. pegylated interferon-alpha-2a (n = 3) and atorva-
statin) [7]. Of the 66 suspected ADR-medicine combina-
tions, the causality according to the Naranjo score was
“probable” in 17% and “possible” in 83%. The ADR
was mentioned in the drug label in 59% of combinations,
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in literature in 6% and 35% could not be found in the
label, nor in literature. All these ADR-medicine combina-
tions were unique; in Table 2, we depicted two ADR
reports as example and provided comments on missing
data.
To our knowledge, this is the first study examining
spontaneous ADR reports on patients suffering from cir-
rhosis. The number of reports seemed low, suggesting se-
lective reporting or inadequate documentation of cirrhosis
as (co)morbidity. Furthermore, the quality of documenta-
tion was poor; key data on the diagnosis and severity of
cirrhosis were frequently lacking. It is not only important
that reporting of ADRs on these patients is encouraged, but
also that sufficient patient details are requested during
reporting from the treating physicians. The low quantity
and quality of reports limited analyses of the nature of
ADR reports to explore potential drug safety issues in cir-
rhosis. To gain more knowledge on ADRs in patients with
cirrhosis, data from a pharmacovigilance centre could be
combined with post-marketing data from other sources,
such as electronic health records.
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Table 1 Characteristics of spontaneous ADR reports on patients with
cirrhosis
Report characteristics, total number (%) 38 (100)
Reporter
Physician 30 (79)
Pharmacist 5 (13)
Other healthcare professional 2 (5)
Unknown 1 (3)
Seriousness reaction
Death 3 (8)
Life threatening 5 (13)
Hospitalization 11 (29)
Serious 4 (11)
Non-serious 14 (37)
Unknown 1 (3)
Suspected medicines, total number (%) 43 (100)
Number of medicines per report, median (range) 1 (1–3)
Top three most frequently reported drugs, n (%)
Pegylated interferon-alpha-2a 3 (7)
Meropenem 2 (5)
Norfloxacin 2 (5)
Propranolol 2 (5)
Suspected ADRs, total number (%) 58 (100)
Number of ADRs per report, median (range) 1 (1–5)
Top three most frequently reported ADRs, n (%)
Thrombocytopenia 3 (5)
Rash 3 (5)
Seizures 3 (5)
ADR-medicine combinations, total number (%) 66 (100)
Causality according to Naranjo score
Probable 11 (17)
Possible 55 (83)
Data on ADR-drug combination
Described in drug label 39 (59)
Reported in literature (not in drug label) 4 (6)
Not in label, nor in literature 23 (35)
ADR, adverse drug reaction
Table 2 Narrative of two spontaneous adverse drug reaction reports on
patients with cirrhosis
Case 1: 64-year-old female with rhabdomyolysis
Clinical history: Cirrhosis due to alcohol use disorder, type 2 diabetes,
hypertension and hypercholesterolemia.
Suspected medication: Atorvastatin (already used for 8 years and the
last year in a dose of 40 mg twice daily).
Concomitant medication: Spironolactone, hydrochlorothiazide,
metformin, tolbutamide, fluvoxamine, paracetamol/codeine,
metoprolol, thiamine and nystatin. Nystatin (5 mg four times daily)
was started 2 weeks before the event.
Event: Patient was hospitalized for rhabdomyolysis and atorvastatin
was stopped. The outcome is unknown.
Previously described: Drug label
Causality (Naranjo score): Possible
Comments: Rhabdomyolysis is a well-known adverse drug reaction of
atorvastatin. Atorvastatin is highly cleared by the liver which in-
creases the risk of high plasma levels and rhabdomyolysis in patients
with cirrhosis. Pharmacokinetic changes will be larger with an in-
creasing severity of cirrhosis. However, data on the severity of cir-
rhosis is not provided in the report.
Case 2: 75-year-old female with lactic acidosis
Clinical history: Cirrhosis due to non-alcoholic steatohepatitis
(NASH)/auto-immune hepatitis with oesophageal varices, type 2
diabetes, gout, hypercholesterolemia and a hysterectomy.
Suspected medication: Metformin (850 mg twice daily used for
4 years) and spironolactone (increased 3 weeks before the event from
50 mg per day to 200 mg daily).
Concomitant medication: -
Event: Patient was hospitalized for lactic acidosis and both metformin
and spironolactone were stopped. She was recovering.
Previously described: Drug label (metformin), not found
(spironolactone)
Causality (Naranjo score): Possible (for both metformin and
spironolactone)
Comments: Possible interaction between the two medicines;
diuretic-induced renal impairment and dehydration may increase the
risk of lactic acidosis in patients using metformin. In addition, severe
liver dysfunction could lead to reduced tissue perfusion and impaired
lactate clearance. Important information is missing in the documen-
tation (i.e. the severity of cirrhosis and renal function parameters).
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